ResearcherStanford MedicineActive in the last 2 years

Bo He

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-1471-9772; OpenAlex author ID A5000318359. Sources: OpenAlex.

Their work

Papers: 1
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 4

Papers, trials and grants by year

2024: 1 paper

Papers 1

Epigenetic priming targets tumor heterogeneity to shift transcriptomic phenotype of pancreatic ductal adenocarcinoma towards a Vitamin D susceptible state. Co-author DOI 10.1038/s41419-024-06460-9 ↗

Closest collaborators

The 4 strongest of 4 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Sofia Ferreira · 1 shared paper, 2024 · strength 0.18
- Paper Epigenetic priming targets tumor heterogeneity to shift transcriptomic phenotype of pancreatic ductal adenocarcinoma to… DOI 10.1038/s41419-024-06460-9 ↗
Brittany M. Flowers · 1 shared paper, 2024 · strength 0.18
- Paper Epigenetic priming targets tumor heterogeneity to shift transcriptomic phenotype of pancreatic ductal adenocarcinoma to… DOI 10.1038/s41419-024-06460-9 ↗
Jiangbin Ye · 1 shared paper, 2024 · strength 0.18
- Paper Epigenetic priming targets tumor heterogeneity to shift transcriptomic phenotype of pancreatic ductal adenocarcinoma to… DOI 10.1038/s41419-024-06460-9 ↗
Laura D Attardi · 1 shared paper, 2024 · strength 0.18
- Paper Epigenetic priming targets tumor heterogeneity to shift transcriptomic phenotype of pancreatic ductal adenocarcinoma to… DOI 10.1038/s41419-024-06460-9 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.